NeuCyte Licenses Its Novel Neuronal Programming Technology to Enable Academic Research
- jodavila1977
- Dec 6, 2022
- 2 min read
SUNNYVALE, Calif., Dec. 3, 2018 /PRNewswire/ -- NeuCyte, Inc., a leading neuroscience drug discovery company, announced that it has entered a license agreement with Boston Children's Hospital. As part of the agreement, Boston Children's has obtained a non-exclusive license from NeuCyte to manufacture transcription factor Ngn2 programmed induced neurons. The hospital intends to use this technology for internal research, teaching and educational purposes, and to perform services to other academic institutions.
"We are pleased to license this advantageous technology that was originated from Dr. Thomas Südhof's laboratory at Stanford University," said Mustafa Sahin, MD, PhD, director of the Translational Neuroscience Center and Human Neuron Core at Boston Children's and professor of neurology at Harvard Medical School. "We hope this technology will enable us and other researchers to create a tool that closely resembles human biology in vitro and will become an important part of our effort to improve human health."
"NeuCyte has the exclusive rights to Stanford's original neuronal induction technology and has further developed it to incorporate into our proprietary in vitro drug discovery platforms," said Jonathan Davila, PhD, Co-founder and CEO of NeuCyte. "We are happy to get the technology into the hands of Boston Children's Hospital where it can be further used for academic research. We also welcome discussions with other organizations who are interested in this technology."
About NeuCyte, Inc. NeuCyte is an innovative biotechnology company focused on developing impactful medicines for improving the lives of patients suffering from neurological disorders. Based on its proprietary SynFire® technology for generating human induced pluripotent stem cell (iPSC)-derived induced neural cells, NeuCyte has developed a highly functional in vitro platform for target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. With the vast knowledge brought by its staff and scientific advisory board, NeuCyte is actively pursuing drug discovery programs for the treatment of Fragile X Syndrome, Epilepsy, ALS and more.
Contact: Ji Wu 1230 Bordeaux Drive Sunnyvale, CA 94089 ji.wu@neucyte.com
This partnership between NeuCyte and Boston Children's Hospital is a remarkable step forward in neuroscience research. The non-exclusive license of the Ngn2 programmed induced neurons offers incredible potential for creating in vitro models that closely resemble human biology, a crucial tool for advancing our understanding of neurological disorders. NeuCyte's SynFire® technology and its focus on neurological diseases like Fragile X Syndrome, Epilepsy, and ALS could significantly impact future treatments. This innovative collaboration not only fosters academic research but also demonstrates the value of specialized expertise, similar to how seeking HR Assignment Help can provide students with the right resources to tackle complex subjects in their academic and professional lives. This kind of scientific partnership paves the way for meaningful progress in…
PHP assignments can be challenging, especially when dealing with complex coding and debugging issues. Students often struggle with syntax errors, database connectivity, and server-side scripting, making it difficult to complete their tasks on time. If you’re thinking, “Who can do my PHP assignment?”, MyAssignmenthelp is here to assist you. Our experienced programmers provide high-quality, plagiarism-free solutions tailored to your needs. With timely delivery and expert guidance, you can master PHP effortlessly and achieve top grades.